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Though commonly used for adjustment of risk, severity of illness and mortality risk
prediction scores, based on the first 24 h of intensive care unit (ICU) admission, have
not been validated in the pediatric extracorporeal membrane oxygenation (ECMO)
population. We aimed to determine the association of Pediatric Index of Mortality 2
(PIM2), Pediatric Risk of Mortality Score III (PRISM III) and Pediatric Logistic Organ
Dysfunction (PELOD) scores with mortality in pediatric patients on ECMO. This was a
retrospective cohort study of children ≤18 years of age included in the Pediatric ECMO
Outcomes Registry (PEDECOR) from 2014 to 2018. Logistic regression and Receiver
Operating Characteristics (ROC) curves were used to calculate the area under the curve
(AUC) to evaluate association of mortality with the scores. Of the 655 cases, 289 (44.1%)
did not survive until hospital discharge. AUCs for PIM2, PRISM III, and PELOD predicting
mortality were 0.52, 0.52, and 0.51 respectively. PIM2, PRISM III, and PELOD scores
are not associated with odds of mortality for pediatric patients receiving ECMO. These
scores for a general pediatric ICU population should not be used for prognostication or
risk stratification of a select population such as ECMO patients.
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INTRODUCTION
Tools to gauge severity of illness (SOI) and predict outcomes for children treated with
extracorporeal membrane oxygenation (ECMO) can facilitate medical decision making, counseling
of patients’ families, and prognostication. ECMO is a cardio-pulmonary support modality for
patients in severe cardiac and/or respiratory failure. It can be a life-saving therapy for patients who
might otherwise not survive but is associated with significant morbidity and mortality. Patients
requiring ECMO have increased severity of illness than the average pediatric intensive care unit
(PICU) patient and have higher mortality (1).
Various scores are commonly used in PICUs worldwide for standardization of risk
of mortality for both clinical benchmarking and for stratification of patient groups for
research purposes. It is not uncommon to include markers of SOI or predictors of
mortality in multivariable analysis to adjust for illness severity in comparing patients.
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III, and PELOD scores were then calculated. Other variables
collected included demographic information such as sex and
race, and clinical variables such as time from PICU admission
to cannulation, weight, mode of ECMO cannulation, history of
in-hospital cardiopulmonary arrest prior to ECMO, and ECPR
which was defined as actively receiving CPR at the time of
cannulation. The following variables were collected as markers
of illness severity at the time of ECMO cannulation: urine output
8, 16, and 24 h prior to ECMO, highest lactate, total bilirubin,
International Normalized Ratio (INR), platelet count, C-reactive
protein (CRP), and creatinine in the 24 h prior to ECMO. OI was
calculated within 6 h prior to cannulation, and VIS determined
immediately prior to cannulation (8, 9).

These include Pediatric Index of Mortality 2 (PIM2), Pediatric
Risk of Mortality Score III (PRISM III), and Pediatric Logistic
Organ Dysfunction (PELOD) (2–4). While the validation set for
these scores had an area under the curve (AUC) of >0.9 for
outcome prediction, (2–4) they were calibrated for the general
PICU population. They are calculated using data in the first 1 h
(PIM2) or 24 h of PICU admission (PRISM III, PELOD) and
significant variation in a patient’s clinical course may exist from
the time of score calculation on admission to when patients
are cannulated onto ECMO. Illness severity scores validated for
general PICU populations are sometimes used to adjust risk
in specific populations, such as patients with hemophagocytic
lymphohistiocytosis, those receiving renal replacement therapy,
therapeutic plasma exchange, etc. (5–7). While these scores are
also used in studies for pediatric patients on ECMO, there is
however limited data on the ability of these scores to predict
mortality in this select cohort. Knowing the validity of these
illness severity scores in children receiving ECMO is needed to
determine the appropriate of their use for clinical and research
purposes in this cohort.
We sought to determine the association of PIM2, PRISM
III, and PELOD scores calculated on admission to the PICU
with mortality in pediatric patients treated with venovenous
(VV) or venoarterial (VA) ECMO. We hypothesized that these
scores would not be associated with outcomes for children
receiving ECMO.

Statistical Analysis
Patient and clinical characteristics were summarized using mean
with standard deviation, median with 25 and 75th percentiles,
and frequency with percentage. The summary statistics were
stratified by mortality and compared using two sample t-test,
Wilcoxon rank sum test, Fisher’s exact test, or Chi-square
test, as appropriate. Logistic regression and Receiver Operating
Characteristics (ROC) curves were used to calculate the area
under the curve (AUC) for predicting mortality with PIM2,
PRISM III, and PELOD to assess discrimination. The ROC curves
were compared to each other. Calibration of the model based on
the deciles of risk by the relevant score was performed using the
Hosmer-Lemeshow test. Subgroup analyses were decided on a
priori and included the VV, VA and ECPR cohorts, as well as early
cannulation, defined as patients cannulated within the first 2 days
of PICU admission. Statistical analyses were performed using
Stata v 15.1 (Stata Corp, College Station, TX). For the calibration
test a p-value >0.05 indicates a good model fit. For other analyses,
a p-value of <0.05 was set as statistically significant a priori.

METHODS
We conducted a retrospective cohort study of patients in the
Pediatric ECMO Outcomes Registry (PEDECOR) cannulated
on ECMO from 2014 to 2018. PEDECOR is a web-based data
platform, housed at Baylor College of Medicine’s Dan L. Duncan
Institute for Clinical and Translational Research. While initially
built to support anticoagulation in ECMO research for BloodNet,
a subgroup of PALISI (Pediatric Acute Lung Injury and Sepsis
Investigators), it has expanded to include a robust clinical,
laboratory and medication dataset for patients on ECMO. There
were 10 U.S. children’s hospitals participating in the registry.
All participating institutions were trained on data entry; a
data dictionary was provided, and two-person verification was
undertaken at each site for interrater validation.
Baylor College of Medicine’s Institutional Review Board
approved the study protocol and waived the need for informed
consent. We included all patients ≤ 18 years of age at the time of
PICU admission. Children cannulated at an outside hospital and
subsequently transferred to a PEDECOR site were excluded. We
excluded patients in the registry prior to 2014 and those without
mortality information. Patients that were missing all three scores
were excluded from the study; we included patients with at least
one of the three scores. For patients with multiple ECMO runs,
only the first ECMO run was included in the analysis.
PIM2, PRISM III, and PELOD scores were directly added
to the case report form if available to a study site, otherwise
the individual variables comprising the score were directly
entered into the online form from which the PIM2, PRISM

Frontiers in Pediatrics | www.frontiersin.org

FIGURE 1 | Study inclusion and exclusion flow diagram.
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RESULTS

ability to discriminate mortality (10). The study was limited to
178 pediatric patients with respiratory failure on veno-venous
ECMO. The validity of these scores in pediatric patients treated
with veno-arterial ECMO for respiratory and cardiac failure was
not studied. Our results, using a different data set, validate the
previous finding that PIM2, PRISM III, and PELOD scores do
not discriminate for death in pediatric patients receiving VV
ECMO for respiratory failure, in a more diverse cohort across
several institutions. Our study also shows that, in addition to VV
patients, these scores have poor discrimination with mortality for
patients receiving VA ECMO, as well as the overall larger cohort
of 655 patients
PIM2, PRISM III, and PELOD scores are based on parameters
collected within the first few hours of admission to the PICU.
PICU lengths of stay can range from days to even months, and
a patient’s clinical course can be highly variable influenced in
part by the various therapies administered as well as individual
patient responses to treatment. Cannulation for ECMO is often
remote from admission, and scores calculated based on variables
at the time of admission less accurately reflect the clinical state
at the time of cannulation. We sought to determine if the scores
performed better when applied to patients cannulated closer to
the time the score was calculated. For the subgroup of patients
cannulated within 2 days of PICU admission, 50% of study
cohort, PRISM III had the highest AUC of 0.6 among the scores,
which is far from ideal for a prognostic tool, and vastly inferior to
the AUC of 0.9 for the overall PICU population. These SOI scores
are not adequate for discrimination of mortality even when
applied to patients who go on to receive ECMO cannulation
closer to when the scores are calculated.
Severity of illness scores developed for the general PICU
population are often used in research studies to compare patients
based on illness severity. They have also been used to describe
illness severity as well as risk of mortality in pediatric patients on
ECMO. The PRISM score was used in the description of patients
with meningococcal disease that were supported on ECMO (11)
and in pediatric ECMO patients with acute respiratory failure
(12). Even more recent studies such as a study on delirium in
pediatric patients on VA ECMO in a cardiac ICU have used
the PRISM III score to assess risk of mortality of patients
in their cohort (13). PIM2, PELOD and PRISM scores were
used in the baseline comparison of groups of patients who did
not undergo tracheostomy vs. those that underwent an early
or late tracheostomy after ECMO cannulation (14). Our study
found that these scores cannot discriminate survivors from nonsurvivors after ECMO, hence they should not be used to compare
baseline illness severity or to correlate outcomes. These general
ICU scores used for risk stratification in focused populations are
not valid for patients on ECMO.

Seven hundred fifty six ECMO runs were evaluated in pediatric
patients ≤18years. There were 655 patients in the registry
that met inclusion and exclusion criteria (Figure 1). Prior
to hospital discharge 289 (44.1%) patients died overall, with
a mortality of 26.5% for VV cannulations and 49.1% for
VA cannulations. Table 1 presents the summary statistics for
patient and ECMO course characteristics by mortality. Table 2
presents the diagnostic indications for ECMO by survival and
by cannulation type. Mortality was also higher for ECPR patients
and those who received in-hospital CPR prior to ECMO.
The odds of mortality were not associated with PIM2, PRISM
III, or PELOD scores (Table 3 and Figure 2). The AUC for
PIM2 was 0.52 (Figure 3), for PRISM III was 0.52 (Figure 4)
and for PELOD was 0.51 (Figure 5). There was no difference
in the performance of these scores for patients on VV or
VA ECMO (Supplementary Figures 1, 2). Subgroup analysis of
early cannulation, showed that of the three scores, PRISM III
performed slightly better at predicting mortality in this cohort
with an AUC of 0.60 (Supplementary Figure 3). Table 4 presents
the AUC and 95% confidence intervals for PIM2, PRISM III,
and PELOD, with mortality for all patients, by cannulation
type, and by timing of ECMO start. AUC’s range from 0.47
up to 0.60 indicating poor discrimination. Hosmer-Lemeshow
goodness of fit test indicates adequate calibration by score deciles
for the entire cohort, the VV ECMO group, the VA ECMO
group, and the group cannulated after 2 days. Calibration was
poor among those cannulated earlier than 2 days, and for
PELOD (p = 0.0195) but was adequate for PIM2 and PRISM III
(Supplementary Table 1).

DISCUSSION
Multiple scores have been developed for the general PICU
population for use in clinical bench marking and in research
stratification by adjusting the expected risk of mortality for
degree of illness. PIM2, a revised version of Pediatric Index of
Mortality, is a risk of mortality score published in 2003 (3).
It was developed using patient data gathered during the first
hour of ICU admission from 12 units in Australia, New Zealand
and the United Kingdom. PRISM III, a revision of the PRISM
score, is a pediatric physiology-based score for mortality risk
published in 1996. It was a U.S. study, validated using 17 clinical
variables from the first 24 h of admission to the study site ICU (4).
PELOD is a score for the assessment of multi-organ dysfunction,
developed in 1999 and validated in 2003. It includes 10 variables
corresponding to 5 organ dysfunctions with data collected from
the first 24 h of admission to ICU (2). These scores have been
validated in the general PICU population with AUC >0.9 for
mortality outcome prediction. They have been used for mortality
outcome prediction in specific groups of patients, such as those
supported with ECMO, even though they were not originally
created for this purpose.
Until recently, there were no data available on whether
these three scores were appropriate for discriminating mortality
risk in children treated with ECMO. Barbaro et al. showed
that the PIM2, PRISM III, and PELOD scores had poor
Frontiers in Pediatrics | www.frontiersin.org

LIMITATIONS
Limitations of this study are variation of clinical practice among
different centers, missing data, and limitation of analysis to the
variables collected in the registry. The PIM2, PRISM III, and
PELOD scores were contemporary at the start of the PEDECOR
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TABLE 1 | Summary statistics compared between survivors and non-survivors at time of discharge.
Alive (total N = 366)
Variable

Died (total N = 289)

N %, mean (SD) or

N

N %, mean (SD) or

N

median (IQR)

P-value

median (IQR)

Demographics
Age at ECMO (yr)*

366

0.3

(0.0,4.2)

289

0.3

(0.0,4.7)

0.374

Weight (kgs)*

318

5

(3.4,13.5)

251

4.6

(3.2,14.8)

0.401

Male gender

366

199

54.4%

289

155

53.6%

Race

360

278

American Indian or Alaska Native

1

0.3%

0

0%

Asian

9

2.5%

12

4.3%

Black or African American

99

27.5%

71

25.5%

White

220

61.1%

162

58.3%

Other

31

8.6%

33

11.9%

111

30.4%

40

14%

Cannulation type

365

VV
VA

285
254

69.6%

366

1

(0.0,4.0)

CRP (mg/dl)*

44

2.7

INR*

228

1.4

Time to cannulation (days)

0.875
0.33

< 0.001
245

86%

289

2

(0.0,9.0)

0.013

(0.5,9.4)

13

2.2

(0.8,6.5)

0.947

(1.2,1.9)

165

1.7

(1.3,2.2)

0.006

Pre-cannulation laboratory values

Highest arterial lactate (mmol/L)*
Entire cohort

178

3

(1.4,8.1)

126

7.1

(2.3,16.1)

< 0.001

VA ECMO cohort

121

3.9

(2.1, 11.3)

107

9.5

(2.9, 17.5)

< 0.001

Highest creatinine (mg/dl)*

332

0.6

(0.4,0.8)

252

0.7

(0.5,1.0)

< 0.001

Platelets (k/mm3)*

276

167

(98.5,249.5)

208

127

(86.5,212.0)

Bilirubin (mg/dl)*

117

1.3

(0.4,3.4)

101

1.3

(0.5,3.3)

0.951

Hemoglobin (g/dl)∧

282

12.7

(2.7)

209

11.8

(3)

0.001

8 h prior

292

0.4

(0.1,1.0)

228

0.3

(0.1,0.8)

0.012

16 h prior

285

1

(0.3,1.9)

227

0.8

(0.2,1.7)

0.071

24 h prior

280

1.4

(0.4,3.0)

230

1.2

(0.3,2.6)

0.203

Entire cohort

249

30

(6.0,48.0)

154

20.5

(5.0,45.0)

0.186

VV ECMO cohort

93

39

(23.0, 55.0)

37

43

(25.0, 62.0)

0.358
0.044

0.003

Urine output prior to ECMO (ml/kg/h)*

Severity of illness variables
Oxygenation index*

Vasoactive inotrope score*
VA ECMO cohort

232

20.6

(8.5, 44.2)

226

25

(10.0, 75.0)

PIM2∧

363

−2.5

(1.9)

284

−2.2

(1.9)

0.088

PRISM III∧

352

14.7

(8.9)

278

15.9

(10.4)

0.117

PELOD∧

359

15.6

(10.8)

286

16.6

(13)

0.273

Entire cohort

365

72

19.7%

287

97

33.8%

< 0.001

VA ECMO cohort

253

65

25.7%

244

93

38.1%

0.004

Entire cohort

365

56

15.3%

286

102

35.7%

< 0.001

VA ECMO cohort

253

53

20.9%

243

100

41.2%

< 00.001

CPR prior to ECMO

ECPR

* Median

(25th, 75th percentiles).
(SD).
ECMO, extracorporeal membrane oxygenation; VV, venovenous; VA, venoarterial; CRP, C reactive protein; INR, international normalized ratio; PIM2 pediatric index of mortality 2; PRISM
III, pediatric risk of mortality score III; PELOD, pediatric logistic organ dysfunction; CPR, cardiopulmonary resuscitation; ECPR, extracorporeal cardiopulmonary resuscitation.
∧ Mean

Frontiers in Pediatrics | www.frontiersin.org
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TABLE 2 | Diagnostic indications for ECMO.
Reason for ECMO

All patients

ARDS due to trauma

Alive

Dead

VV

VA

3 (0.5%)

1 (0.3%)

2 (1%)

1 (1%)

2 (0.4%)

ARDS, other

121 (19%)

78 (22%)

43 (15%)

60 (41%)

61 (12%)

Arrhythmia

74 (11%)

28 (8%)

46 (16%)

2 (1%)

72 (15%)

Aspiration

25 (4%)

16 (5%)

9 (3%)

9 (6%)

16 (3%)

Cardiomyopathy-hypertrophic

5 (1%)

2 (1%)

3 (1%)

0

5 (1%)

Cardiomyopathy-restrictive

3 (0.5%)

0

3 (1%)

0

3 (1%)

Cardiomyopathy-dilated

33 (5%)

20 (6%)

13 (5%)

1 (1%)

32 (6%)

Congenital diaphragmatic hernia

68 (11%)

41 (11%)

27 (9%)

17 (12%)

50 (10%)

Congenital heart disease

186 (29%)

85 (24%)

101 (35%)

2 (1%)

181 (37%)
10 (2%)

Coronary artery anomaly

10 (2%)

5 (1%)

5 (2%)

0

Cystic fibrosis

1 (0.2%)

1 (0.3%)

0

1 (0.7%)

0

Drug intoxication

3 (0.5%)

2 (0.6%)

1 (0.4%)

0

3 (0.6%)

Hemophagocytic lymphohistiocytosis

1 (0.2%)

0

1 (0.4%)

0

1 (0.2%)

Hyperosmolar non-ketotic hyperglycemia

1 (0.2%)

1 (0.3%)

0

0

1 (0.2%)

Inborn error of metabolism

1 (0.2%)

1 (0.2%)

1 (0.3%)

0

0

Interstitial lung disease

6 (1%)

2 (1%)

4 (1%)

3 (2%)

3 (1%)

meconium aspiration

9 (1%)

9 (3%)

0

8 (5%)

1 (0.2%)

Myocarditis

26 (4%)

18 (5%)

8 (3%)

0

26 (5%)

Pneumonia

70 (11%)

48 (13%)

22 (8%)

51 (35%)

19 (4%)

Post-transplant graft failure—heart

18 (3%)

13 (4%)

5 (2%)

0

18 (4%)

Primary pulmonary hypertension

60 (9%)

38 (11%)

22 (8%)

9 (6%)

51 (10%)

Pulmonary embolus

3 (0.5%)

2 (0.6%)

1 (0.4%)

0

3 (0.6%)

Pulmonary hypertension (non-PPHN)

27 (4%)

15 (4%)

12 (4%)

8 (5%)

18 (4%)

Sepsis

61 (9%)

21 (6%)

40 (14%)

8 (5%)

53 (11%)

Status asthmaticus

19 (3%)

17 (5%)

2 (1%)

16 (11%)

3 (1%)

Submersion injury

6 (1%)

2 (1%)

4 (1%)

2 (1%)

3 (1%)

Six hundred forty six patients had a reason for ECMO provided. Nine patients with a missing indication included one dead, eight alive, four VV, five VA.
N for all reasons for ECMO exceeds total number of cohort patients as some patients had more than one reason for ECMO listed.

TABLE 3 | Logistic regression and odds of mortality.
Odds ratio

95% Confidence interval

P-value

PIM2

1.07

0.99

1.17

PRISM III

1.01

1.00

1.03

0.088
0.118

PELOD

1.01

0.99

1.02

0.273

PIM2, pediatric index of mortality 2; PRISM III, pediatric risk of mortality score III; PELOD,
pediatric logistic organ dysfunction.

registry in 2013. While updated versions now exist for each
of these scores, similar to the iterations of the scores used in
this study, these recent iterations were again validated for a
general pediatric ICU population, and again the score may be
calculated remote to the cannulation date. This paper was limited
to the performance of PIM2, PRISM III, and PELOD scores
and did not evaluate all illness severity scores used in critically
ill children. We did not seek to compare the performance of
newer outcome prediction scores for children requiring ECMO
for respiratory indications such as P-PREP (Pediatric Pulmonary
Rescue With Extracorporeal Membrane Oxygenation Prediction
Score) or PED-RESCUERS (Pediatric Risk Estimate Score for
Children Using Extracorporeal Respiratory Support) (15, 16).

Frontiers in Pediatrics | www.frontiersin.org

FIGURE 2 | Score distributions for survivors and non-survivors.

CONCLUSION
Commonly used SOI scores- PIM2, PRISM III, and PELOD
are not associated with mortality for pediatric patients receiving
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FIGURE 3 | Receiver operating characteristic (ROC) curve and Logistic
regression for Pediatric Index of Mortality 2 (PIM2) predicting mortality.

FIGURE 5 | Receiver operating characteristic (ROC) curve and Logistic
regression for Pediatric Logistic Organ Dysfunction (PELOD) predicting
mortality.

TABLE 4 | Area under the curve (AUC) for severity of illness scores predicting
mortality.
Variable

N

AUC

95% Confidence interval

PIM2

647

0.52

0.48

PRISM III

630

0.52

0.48

0.57

PELOD

645

0.51

0.47

0.56

PIM2

151

0.56

0.46

0.66

PRISM III

146

0.52

0.42

0.63

PELOD

147

0.52

0.41

0.62

PIM2

491

0.50

0.45

0.55

PRISM III

479

0.53

0.47

0.58

PELOD

493

0.52

0.46

0.57

PIM2

338

0.56

0.50

0.63

PRISM III

331

0.60

0.54

0.66

ECMO. This lack of discrimination persists for patients receiving
VA, VV or those cannulated within 2 days of ICU admission.
These scores should not be used by clinicians for medical decision
making or prognostication for ECMO patients. They should not
be used in research studies involving patients that receive ECMO
to compare baseline illness severity between groups of patients.

PELOD

335

0.56

0.50

0.62
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